Berkeley Capital Partners’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.5M | Sell |
24,697
-12,272
| -33% | -$715K | 0.35% | 62 |
|
|
2025
Q4 | $1.99M | Sell |
36,969
-16,397
| -31% | -$789K | 0.47% | 35 |
|
|
2025
Q3 | $2.41M | Buy |
53,366
+4,294
| +9% | +$201K | 0.57% | 30 |
|
|
2025
Q2 | $2.27M | Buy |
49,072
+4,305
| +10% | +$211K | 0.58% | 29 |
|
|
2025
Q1 | $2.73M | Buy |
44,767
+271
| +0.6% | +$15.8K | 0.75% | 23 |
|
|
2024
Q4 | $2.52M | Sell |
44,496
-2,882
| -6% | -$161K | 0.7% | 22 |
|
|
2024
Q3 | $2.45M | Sell |
47,378
-1,991
| -4% | -$93.4K | 0.7% | 23 |
|
|
2024
Q2 | $2.05M | Buy |
49,369
+8,626
| +21% | +$386K | 0.62% | 28 |
|
|
2024
Q1 | $2.21M | Buy |
40,743
+18,546
| +84% | +$945K | 0.67% | 24 |
|
|
2023
Q4 | $1.14M | Sell |
22,197
-1,432
| -6% | -$75.2K | 0.38% | 50 |
|
|
2023
Q3 | $1.37M | Sell |
23,629
-1,033
| -4% | -$63.3K | 0.5% | 38 |
|
|
2023
Q2 | $1.58M | Buy |
24,662
+4,016
| +19% | +$269K | 0.56% | 36 |
|
|
2023
Q1 | $1.43M | Buy |
20,646
+181
| +0.9% | +$12.8K | 0.53% | 37 |
|
|
2022
Q4 | $1.47M | Buy |
20,465
+989
| +5% | +$74.6K | 0.57% | 35 |
|
|
2022
Q3 | $1.39M | Buy |
19,476
+1,846
| +10% | +$134K | 0.6% | 24 |
|
|
2022
Q2 | $1.36M | Buy |
17,630
+1,658
| +10% | +$126K | 0.56% | 25 |
|
|
2022
Q1 | $1.17M | Buy |
15,972
+6,015
| +60% | +$404K | 0.46% | 34 |
|
|
2021
Q4 | $621K | Buy |
9,957
+1,737
| +21% | +$102K | 0.26% | 64 |
|
|
2021
Q3 | $486K | Sell |
8,220
-24
| -0.3% | -$1.58K | 0.22% | 68 |
|
|
2021
Q2 | $551K | Buy |
8,244
+6
| +0.1% | +$391 | 0.25% | 61 |
|
|
2021
Q1 | $520K | Buy |
8,238
+280
| +4% | +$17.4K | 0.25% | 61 |
|
|
2020
Q4 | $494K | Buy |
7,958
+1,059
| +15% | +$65.1K | 0.25% | 61 |
|
|
2020
Q3 | $416K | Sell |
6,899
-8,499
| -55% | -$512K | 0.25% | 61 |
|
|
2020
Q2 | $905K | Sell |
15,398
-4,374
| -22% | -$262K | 0.56% | 29 |
|
|
2020
Q1 | $1.1M | Buy |
19,772
+12,854
| +186% | +$786K | 0.75% | 20 |
|
|
2019
Q4 | $444K | Buy |
6,918
+487
| +8% | +$27.9K | 0.23% | 85 |
|
|
2019
Q3 | $326K | Sell |
6,431
-226
| -3% | -$10.6K | 0.17% | 103 |
|
|
2019
Q2 | $302K | Buy |
6,657
+128
| +2% | +$5.96K | 0.14% | 114 |
|
|
2019
Q1 | $311K | Sell |
6,529
-8,200
| -56% | -$408K | 0.15% | 110 |
|
|
2018
Q4 | $766K | Sell |
14,729
-5,077
| -26% | -$273K | 0.43% | 46 |
|
|
2018
Q3 | $1.23M | Sell |
19,806
-114
| -0.6% | -$6.76K | 0.69% | 28 |
|
|
2018
Q2 | $1.1M | Buy |
19,920
+1,182
| +6% | +$63.8K | 0.64% | 34 |
|
|
2018
Q1 | $1.19M | Buy |
18,738
+337
| +2% | +$21.7K | 0.68% | 30 |
|
|
2017
Q4 | $1.13M | Sell |
18,401
-79
| -0.4% | -$4.94K | 0.74% | 29 |
|
|
2017
Q3 | $1.18M | Buy |
18,480
+13,218
| +251% | +$772K | 0.79% | 28 |
|
|
2017
Q2 | $293K | Sell |
5,262
-2,046
| -28% | -$111K | 0.2% | 95 |
|
|
2017
Q1 | $397K | Buy |
7,308
+99
| +1% | +$5.43K | 0.27% | 84 |
|
|
2016
Q4 | $421K | Buy |
7,209
+378
| +6% | +$20.7K | 0.3% | 76 |
|
|
2016
Q3 | $368K | Sell |
6,831
-197
| -3% | -$12.7K | 0.26% | 79 |
|
|
2016
Q2 | $517K | Buy |
7,028
+90
| +1% | +$6.36K | 0.36% | 66 |
|
|
2016
Q1 | $443K | Buy |
6,938
+1,708
| +33% | +$108K | 0.32% | 66 |
|
|
2015
Q4 | $360K | Buy |
+5,230
| New | +$346K | 0.29% | 69 |
|
Other funds holding BMY
VCM
VPM
Berkeley Capital Partners's BMY Position: Q1 2026 in Review
Berkeley Capital Partners reduced its Bristol-Myers Squibb (BMY) stake by 33% in Q1 2026, selling an estimated $715K and leaving 24,697 shares worth $1.5M. The position accounts for 0.35% of the portfolio, ranked #62.
Berkeley Capital Partners first reported a position in BMY in Q4 2015 and has held it in 42 quarters since. The position peaked at $2.73M in Q1 2025. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Berkeley Capital Partners held 24,697 shares of Bristol-Myers Squibb worth $1.5M as of Q1 2026.
- Berkeley Capital Partners sold 12,272 Bristol-Myers Squibb shares in Q1 2026, an estimated $715K.
- Bristol-Myers Squibb made up 0.35% of Berkeley Capital Partners's portfolio in Q1 2026, its #62 holding.
- Berkeley Capital Partners first reported a position in Bristol-Myers Squibb in Q4 2015 and has held it in 42 quarters since.
- Berkeley Capital Partners's Bristol-Myers Squibb position peaked at $2.73M in Q1 2025.
- 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Berkeley Capital Partners's 13F filing for Q1 2026, filed 7 May 2026.